Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

NAGE - Niagen Bioscience, Inc. So'nggi... | Finranks

Home

NAGE

N

Niagen Bioscience, Inc. (NAGE)

NCM – Real vaqt narxi. Valyuta: USD

4.20

-0.27 (-6.04%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

4.19

-0.01 (-0.24%)

Bozordan keyin: Mar 27, 2026, 7:54 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Niagen Bioscience Increases Share Repurchase Program to $20 Million

Niagen Bioscience Increases Share Repurchase Program to $20 Million

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has authorized an increase to the Company's previously disclosed share repurchase program (the “Program”), raising the total authorization from $10 million to $20 million of the Company's outstanding common stock. Through March 17, 2026, the Company has repurchased approxim.

Niagen Bioscience to Present at the 38th Annual ROTH Conference

Niagen Bioscience to Present at the 38th Annual ROTH Conference

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the 38th Annual ROTH Conference, taking place at The Ritz-Carlton Laguna Niguel in Dana Point, California, from March 22 to 24, 2026. Niagen Bioscience CEO, Rob Fried, will participate in the Technologies Advancing Healthy Aging Panel on Monday, March 23, at.

Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its external research program has surpassed 300 material transfer agreements (MTAs) with investigators and research institutions around the world, marking a major milestone for what the Company believes is the most extensive dedicated NAD+ research support program in the world. Rob Fried, CEO, Ni.

Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Niagen® Skincare Innovation Lab, a new product innovation platform designed to translate the Company's leadership in NAD+ science into category-defining skincare. Debuting under the platform is Niagen NanoCloud™, a limited-release, dermatologist-tested topical skincare product powered by.

Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript

Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript

Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript

Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates

Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates

Niagen Bioscience (NAGE) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.03 per share a year ago.

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results. Fourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter Total net sales increased 16% to $33.8 million, with Tru Niagen® sales of $27.5 million, up 21% from the prior year quarter. Gross margin increased 160 basis points to 64.1%. Net income of $4.1 million compared to $7.2 million in the prior year quarter. Q4 2024 benefited from a $3.5.

Videolar

No Data

There is no data to display

Press-relizlar

Niagen Bioscience Increases Share Repurchase Program to $20 Million

Niagen Bioscience Increases Share Repurchase Program to $20 Million

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has authorized an increase to the Company's previously disclosed share repurchase program (the “Program”), raising the total authorization from $10 million to $20 million of the Company's outstanding common stock. Through March 17, 2026, the Company has repurchased approxim.

Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its external research program has surpassed 300 material transfer agreements (MTAs) with investigators and research institutions around the world, marking a major milestone for what the Company believes is the most extensive dedicated NAD+ research support program in the world. Rob Fried, CEO, Ni.

Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Niagen® Skincare Innovation Lab, a new product innovation platform designed to translate the Company's leadership in NAD+ science into category-defining skincare. Debuting under the platform is Niagen NanoCloud™, a limited-release, dermatologist-tested topical skincare product powered by.

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results. Fourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter Total net sales increased 16% to $33.8 million, with Tru Niagen® sales of $27.5 million, up 21% from the prior year quarter. Gross margin increased 160 basis points to 64.1%. Net income of $4.1 million compared to $7.2 million in the prior year quarter. Q4 2024 benefited from a $3.5.